Q32 Bio (QTTB) Stock
Biotech company developing gene therapies for rare genetic diseases. Here's the price, business snapshot, and what's worth knowing about Q32 Bio in October 2026.
Homology Medicines Inc (QTTB) is a small-cap biotechnology company focused on developing gene editing and gene therapy approaches for rare genetic diseases. With a market capitalisation around $36.2 million, it is an early-stage developer: clinical data, regulatory milestones, partnerships and financing will be the main drivers of value. Investors should expect high volatility, potential dilution from future fundraising and long timelines typical of biotech development. Key areas to watch include cash runway, trial results, intellectual property position and competitor activity in similar gene therapies. The company’s prospects hinge on scientific validation and regulatory approvals — outcomes that are inherently uncertain. This summary is general, educational information only and not personalised investment advice; values can rise or fall and past performance is not a reliable indicator of future returns. Consider your risk tolerance and seek independent financial advice before making investment decisions.
Q32 Bio (QTTB) Stock Forecast
Analyst price target, next 12 months
$31.83
+286.8% vs today's $8.23
Price range over the last 12 months
In the middle of its 12-month range
Analysts covering Q32 Bio have a consensus 12-month target of $31.83, above the current price of $8.23.
Analyst targets are opinions, not guarantees. Capital at risk. Data as of 7 Jul 2026.
Source: Analyst sentiment is provided by Refinitiv Ltd, a global leader in financial market data with over 40k business clients. Refinitiv Ltd is an independent third party to Nemo. This is not advice.
Sixth Month Growth Performance
Stock Performance Snapshot
Analyst Rating
Analysts recommend buying Q32 BIO INC's stock, expecting its price to rise significantly.
Financial Health
Q32 BIO INC is performing well with strong revenue and cash flow, indicating healthy operations.
View more stocks by downloading the app for FREE
It only takes 60 seconds.
Why You’ll Want to Watch This Stock
Early-stage gene platform
Focuses on gene editing and therapy programmes; scientific validation can materially affect valuation, though outcomes are uncertain.
Data drives value
Clinical readouts, regulatory steps and partnerships tend to move the share price; investors should expect volatility and binary outcomes.
Balance risk and reward
Small market capitalisation and limited resources create upside and downside potential; consider runway and dilution risk before investing.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
